Open Access

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma

  • Authors:
    • Shigeo Shimose
    • Takumi Kawaguchi
    • Hideki Iwamoto
    • Takashi Niizeki
    • Tomotake Shirono
    • Masatoshi Tanaka
    • Hironori Koga
    • Takuji Torimura
  • View Affiliations

  • Published online on: February 17, 2020     https://doi.org/10.3892/ol.2020.11399
  • Pages: 2667-2676
  • Copyright: © Shimose et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prognosis of patients with intermediate stage hepatocellular carcinoma (HCC) treated with transcatheter arterial chemoembolization (TACE) is unsatisfactory. The present study analyzed the indications for suitable TACE in patients with intermediate stage HCC. Additionally, it was investigated whether further TACE or switching to multi‑kinase inhibitors (MKIs) was more beneficial for patients with HCC recurrence following initial TACE. The present retrospective study included 238 patients with intermediate stage HCC who were initially treated with TACE (median age, 74 years). A decision‑tree analysis was employed to investigate the therapeutic effect profiles and overall survival (OS) rates. In the decision‑tree analysis for OS, complete response (CR) by initial TACE was selected as the most important variable. In the decision‑tree analysis for CR, <3 liver segments with nodule, simple nodular type and within the up‑to‑seven criteria were selected as the first, second and third variables associated with a high CR rate (35‑64%), respectively. In patients with HCC recurrence having ≥3 liver segments with nodule, out of the up‑to‑seven criteria, and Child‑Pugh class A, the median survival time was significantly longer in those who were treated by switching to MKIs compared with further TACE (44.9 vs. 21.9 months; P=0.003). In intermediate stage HCC, the indications for suitable TACE criteria may be ‘<3 liver segments with nodule’, ‘simple nodular type’, and ‘within the up‑to‑seven criteria’. Additionally, in patients who were ineligible for TACE criteria, the switch to MKIs may improve the prognosis compared with further TACE in cases of HCC recurrence following first TACE.
View Figures
View References

Related Articles

Journal Cover

April-2020
Volume 19 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shimose S, Kawaguchi T, Iwamoto H, Niizeki T, Shirono T, Tanaka M, Koga H and Torimura T: Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. Oncol Lett 19: 2667-2676, 2020
APA
Shimose, S., Kawaguchi, T., Iwamoto, H., Niizeki, T., Shirono, T., Tanaka, M. ... Torimura, T. (2020). Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. Oncology Letters, 19, 2667-2676. https://doi.org/10.3892/ol.2020.11399
MLA
Shimose, S., Kawaguchi, T., Iwamoto, H., Niizeki, T., Shirono, T., Tanaka, M., Koga, H., Torimura, T."Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma". Oncology Letters 19.4 (2020): 2667-2676.
Chicago
Shimose, S., Kawaguchi, T., Iwamoto, H., Niizeki, T., Shirono, T., Tanaka, M., Koga, H., Torimura, T."Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma". Oncology Letters 19, no. 4 (2020): 2667-2676. https://doi.org/10.3892/ol.2020.11399